Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma.
Lee M OcuinJeffrey M HardacreJohn B AmmoriLuke D RothermelAmr MohamedJennifer E SelfridgeDavid BajorJordan M WinterPublished in: Journal of surgical oncology (2020)
Neoadjuvant therapy in patients with left-sided pancreatic cancers is associated with improved pathologic outcomes as well as longer overall survival. Neoadjuvant therapy should be considered in all patients with PDAC regardless of tumor location.